Search

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

Tutorial on thalassemia focused on best treatment

Almost 90 delegates from Shiraz and other cities in Iran learned how to identify the best treatment for each thalassemia patient at the EHA-SHRC Hematology Tutorial on Thalassemia on May 10-11, 2018 in Shiraz, Iran.

Read more

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Read more

SWG Educational Activities

EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).

Read more

Mission ‘Gene Therapy’ for Horizon Europe

Mission ‘Gene Therapy’ for Horizon Europe

Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

SWG Education Activities

Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).

Read more

International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia

Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion- dependent children identified each year around the world.

Read more